Abstract:
The BTP report explores the integration of cutting-edge genomics and precision medicine into a comprehensive platform named GenomeX. With a focus on Genome-wide Association Studies (GWAS), the report delves into the methodology of identifying genetic variants associated with various traits, emphasizing the significance of large sample sizes and the analysis of millions of Single Nucleotide Polymorphisms (SNPs). The genomics industry’s exponential growth is outlined, highlighting recent technological advancements such as long-read sequencing, singlecell sequencing, and AI-driven analysis of genomic datasets. The report identifies a compelling opportunity to address the increasing risk of life-threatening illnesses through personalized healthcare. The proposed product, GenomeX, emerges as a rolebased platform offering genetic testing, personalized treatments, expert consultations, and wellness programs. The unique selling points include seamless integration, patient-centric genetic reports, and a secure user-friendly experience. The target audience spans healthcare professionals, organizations, individual users, biotech companies, and research institutions. Furthermore, the report introduces Polymeric Risk Scoring (PRS) as a key feature, explaining its calculation based on the cumulative effect sizes of disease-associated variants. The methodology involves large-scale genotype studies, control groups, and validation studies to assess accuracy. The research culminates in the development of a mobile application and website, presented through screenshots, positioning GenomeX as a pioneer in making precision medicine accessible and actionable for individuals and healthcare providers alike.
